Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 15,000 shares of the stock in a transaction dated Wednesday, August 12th. The stock was purchased at an average cost of $24.47 per share, with a total value of $367,050.00. Following the completion of the purchase, the director directly owned 555,810 shares in the company, valued at approximately $13,600,670.70. This trade represents a 2.77% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Biodesix Trading Down 1.8%

BDSX stock opened at $23.79 on Friday. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. Biodesix, Inc. has a twelve month low of $5.26 and a twelve month high of $25.52. The company has a market cap of $250.98 million, a P/E ratio of -7.50 and a beta of 0.56. The business has a fifty day moving average of $20.33 and a 200-day moving average of $16.13.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.19. The business had revenue of $26.86 million for the quarter, compared to analysts’ expectations of $26.03 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. As a group, equities research analysts expect that Biodesix, Inc. will post -2.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Roth Capital started coverage on shares of Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 price objective on the stock. Canaccord Genuity Group raised their price objective on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.33.

Biodesix News Summary

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Director Jack W. Schuler purchased an additional 15,000 shares for approximately $367,050 at an average price of $24.47 on August 12. Combined with purchases of 13,700 shares on August 11 and 13,900 shares on August 10, Schuler bought 42,600 shares for roughly $1.03 million over three sessions, increasing his direct ownership to 555,810 shares. The buying may signal confidence in Biodesix’s outlook. SEC insider transaction filing
• Positive Sentiment: Biodesix reported second-quarter adjusted performance that exceeded expectations: EPS was negative $0.71 versus the consensus estimate of negative $0.90, while revenue reached $26.86 million compared with an expected $26.03 million. The earnings call transcript provides additional discussion of the results and outlook. Biodesix Q2 2026 earnings call transcript
• Positive Sentiment: Analyst sentiment remains constructive. Canaccord Genuity raised its price target from $27 to $35 while maintaining a Buy rating, and HC Wainwright reiterated Buy with a $27 target. Roth Capital previously initiated coverage with a Buy rating and a $32 target. The reported consensus target is $31.33, above recent trading levels. Biodesix analyst price-target coverage
• Neutral Sentiment: Institutional ownership activity was mixed but included several new positions and additions, including AIGH Capital Management’s approximately $11.0 million stake and increased holdings by XTX Topco. Institutions own about 21% of BDSX.
• Negative Sentiment: Despite the revenue and EPS beat, Biodesix remains unprofitable, with a negative net margin and analysts forecasting approximately negative $2.68 EPS for the current year. Its debt-to-equity ratio of 5.12 also represents a financial risk, particularly after the stock’s substantial advance toward its 52-week high.

Institutional Investors Weigh In On Biodesix

Several large investors have recently bought and sold shares of the company. Allworth Financial LP bought a new position in shares of Biodesix during the second quarter worth $112,000. BlackRock Inc. bought a new position in Biodesix during the second quarter worth about $970,000. AIGH Capital Management LLC acquired a new position in Biodesix in the second quarter valued at about $15,296,000. GSA Capital Partners LLP bought a new stake in shares of Biodesix in the second quarter worth about $1,060,000. Finally, Walleye Capital LLC bought a new stake in shares of Biodesix in the second quarter worth about $1,679,000. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.